Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | IL1B | P01584 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095989 | 0.87 | NR1H4 (0.46) | NR1H4GABRB3DHODHGABRA1GABRG2 | |
| SCHEMBL2772785 | 0.87 | CCR1 (0.34) | NR1H4CCR1P2RX7GABRB3DHODH | |
| SCHEMBL2772320 | 0.80 | DHODH (0.39) | P2RX7GABRB3DHODHHSD11B1GABRA1 | |
| SCHEMBL2773464 | 0.78 | NR1H4 (0.38) | NR1H4CCR1P2RX7DHODH | |
| SCHEMBL2773215 | 0.77 | GABRA1 (0.39) | NR1H4GABRB3DHODHGABRA1GABRG2 | |
| SCHEMBL2774647 | 0.75 | NR1H4 (0.45) | NR1H4NPBWR1MCHR1 | |
| SCHEMBL21340190 | 0.75 | NR1H4 (0.43) | NR1H4PDE9APDE1C | |
| SCHEMBL2775151 | 0.75 | NR1H4 (0.37) | NR1H4P2RX7GABRB3GABRA2GABRB2 | |
| SCHEMBL1096331 | 0.74 | NR1H4 (0.44) | NR1H4NPBWR1MCHR1 | |
| SCHEMBL27896299 | 0.72 | NR1H4 (0.43) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | NR1H4 1/4885CCR1 1483/4885P2RX7 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.